
Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1019 | 886 | 1019 | 1030 | 1069 | 1160 |
Fund Return | 1.89% | -11.42% | 1.89% | 0.99% | 1.35% | 1.49% |
Place in category | 64 | 174 | 64 | 47 | 73 | 57 |
% in Category | 25 | 85 | 25 | 17 | 54 | 70 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Franklin Technology Fund C acc USD | 158.7M | 24.98 | 0.60 | 16.18 | ||
Franklin Technology Fund I acc USD | 923.66M | 26.71 | 2.15 | 17.94 | ||
Franklin Technology Fund W acc USD | 386.11M | 26.68 | 2.11 | 17.86 | ||
Franklin Technology Fund X acc USD | 9.79M | 27.53 | 2.87 | 18.77 | ||
Franklin Technology Fund Z acc USD | 24.58M | 26.66 | 2.89 | 17.59 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Equities L Biotechnology Class R US | 1.08B | 3.48 | 8.71 | 5.94 | ||
Candriam Equities Biotech C USD Cap | 1.08B | 3.56 | 7.84 | 5.10 | ||
LU0133359157 | 1.08B | 3.53 | 7.41 | 4.64 | ||
Equities L Biotechnology Class I US | 1.08B | 2.92 | 2.58 | 5.59 | ||
Pictet Biotech PUSD | 1.04B | 6.64 | 7.56 | 2.65 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Amgen | US0311621009 | 6.05 | 285.98 | +1.62% | |
Vertex | US92532F1003 | 5.82 | 484.22 | +1.84% | |
Gilead | US3755581036 | 5.64 | 103.63 | +2.20% | |
Regeneron Pharma | US75886F1075 | 5.57 | 554.18 | +1.43% | |
Intracellular Th | US46116X1019 | 3.73 | 131.87 | 0.00% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Strong Sell | Strong Sell | Strong Sell |
Technical Indicators | Strong Sell | Strong Sell | Strong Sell |
Summary | Strong Sell | Strong Sell | Strong Sell |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review